11TH INTERNATIONAL CONGRESS ON SPONDYLOARTHRITIDES

4 - 6 October 2018
Gent, Belgium

www.spa-congress.org
Dear colleagues and friends,

Welcome to the Eleventh International Congress on Spondyloarthritides, which takes place from the 4-6th October 2018 in the beautiful city of Gent. The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. Indeed, the attendance has almost quadrupled since 1998 to include scientists, medical doctors, allied health professionals, pharmaceutical industry representatives and people affected by these conditions from all over the world.

The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters. The number of abstracts submitted has remained steady over the years, and so we are expecting to select from around 200 high quality contributions this year.

The programme for the 2018 congress will offer a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics. A highly regarded part of the meeting are the poster sessions which provide the perfect frame for stimulating and interactive multidisciplinary exchanges among attendees. In addition, and following on from the last edition we have planned a lively debate which promises to be educational as well as entertaining.

New this year is the introduction of the “Gent Oration” aimed to honor a scientist or clinician with an established trajectory in the field which we expect with time, to become one of the main highlights of the congress. It is our great pleasure to invite Professor Joachim Sieper as the inaugural Gent orator in this first edition.

The social programme including the Walking Dinner at the Opening Reception, Gala Dinner and Farewell Reception are sure to give you the opportunity to catch up with old and new friends and enjoy the magic of Gent.

As co-presidents of the 11th International Congress on Spondyloarthritides we would like to welcome you to this exciting occasion which we are sure will once again, provide the best platform for vibrant scientific and clinical discussions in all aspects of these fascinating group of diseases.

Helena Marzo-Ortega & Maxime Breban
Thursday, October 4

13.00  Welcome Address
Helena Marzo-Ortega and Maxime Breban

13.15  INV1  Keynote Lecture - The role of microbiome in health and chronic inflammation
Dusko Ehrlich, Jouy-en-Josas, France

SESSION 1:  Tackling the microbiome realm in SpA

14.00  INV2  Innate lymphoid cells at the barrier and inflammation: Halt or go?
Tom Cupedo, Rotterdam, The Netherlands

14.30  INV3  Microbiota in IBD, from inventory to therapeutic intervention
Harry Sokol, Paris, France

15.00  INV4  Microbiome and gut inflammation in HLA-B27 transgenic rat: What is the relationship?
Robert Colbert, Bethesda, USA

15.30  Coffee Break

SESSION 2:  Do women come from Venus and men from Mars? Myths and Truths about gender differences in axial SpA

16.00  INV5  Exploring gender differences in the clinical phenotype and response to treatment in axial SpA
Lianne Gensler, San Francisco, USA

16.30  INV6  So there may be some true after all: What is the underlying biology?
Eric Gracey, Toronto, Canada

17.00  INV7  Painful risk to be female? What we know, and why it is not so trivial!
Walter Magerl, Manheim, Germany

17.30  INV8  Keynote Lecture - The Gent SpA Oration
AS old as time: From bugs to bench to the bedside and back
Joachim Sieper, Berlin, Germany

18.15  Walking Dinner

Friday, October 5

SESSION 3:  Innate cells and cell signaling in SpA

08.45  INV9  The importance of unconventional T cells in inflammation and immunity
Dale Godfrey, Melbourne, Australia

09.15  INV10  How macrophages help resolve inflammation
Kodi Ravichandran, Charlottesville, USA & Gent, Belgium

09.45  INV11  Immune effector cells in SpA: What are the pathways?
Paul Bowness, Oxford, UK

10.15  Poster Session 1 and Coffee Break

SESSION 4:  The auto-inflammation axis in SpA

11.15  INV12  Auto-immunity versus auto-inflammation in eye disease in SpA
John Forrester, Aberdeen, United Kingdom

11.45  INV13  Auto-antigens as drivers of psoriasis: Increasing specificity and efficacy of treatments in skin and joints
Diamant Thaçi, Lübeck, Germany

SESSION 5:  The great debate

12.15  This house believes that “Treat to target” has no place in the treatment of axSpA
INV14  Speaking for: Atul Deodhar, Portland, USA
INV15  Speaking against: Pedro Machado, London, UK

13.00  Lunch
**SESSION 6:**

14.00  INV16  **How peptide loading complex affects MHC class I biology**
Simon Trowitzsch, Germany

14.30  INV17  **HLA-B27 and multiomics: Where does it bring us?**
Henri-Jean Garchon, Paris, France

15.00  INV18  **Is fruit fly relevant to SpA?**
Sébastien Gaumer, Paris, France

**Selected Oral Presentations I**

15.30  O1  **Gut dysbiosis in ankylosing spondylitis is associated with increased fecal calprotectin**
Eva Klingberg, Sweden

15.40  O2  **Inflammasomes activation occurs in the inflamed tissues of AS patients and drives IL-23 expression and ILC3 expansion**
Francesco Ciccia, Italy

15.50  O3  **Transmembrane TNF signaling through TNF-RI induces SpA-like inflammation, whereas signaling through TNF-RII is crucial for new bone formation**
Leonie van Duivenvoorde, The Netherlands

16.00  O4  **PROgnostic Markers In axial Spondyloarthritis (PROMISE) – Alpha 1 anti trypsin and beta 2 microglobulin may differentiate ankylosing spondylitis from non radiographic axSpA, mechanical back pain and healthy controls**
Elizabeth Reilly, UK

16.10  O5  **Impact of gut involvement in early spondyloarthritis - The DESIR cohort**
Daniel Wendling, France

16.20  O6  **Gender differences in TNFi treatment adherence and response in AS patients: A prospective longitudinal cohort study**
Sophie Hoekstra, The Netherlands

16.30  **Poster Session 2 and Coffee Break**

**SESSION 7:**

17.15  INV19  **Genetic studies in AS: Progress and translation**
Matthew Brown, Brisbane, Australia

17.45  INV20  **Lessons from epigenetics for SpA**
Julian Knight, Oxford, UK

18.15  INV21  **Operation Transformation: The impact of genes and life style in joint disease**
Donal O’Shea, Dublin, Ireland

18.45  **Scientific Committee Meeting**

20.00  **Gala Dinner**
Selected oral Presentations II

08.00 07  Fatty lesions detected on MRI scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow
Xenofon Baraliakos, Germany

08.07 08  Prevalence of inflammatory and chronic changes suggestive of axial spondyloarthritis in magnetic resonance images of the axial skeleton in individuals < 45 years in the general population as part of a large community study (SHIP)
Xenofon Baraliakos, Germany

08.15 09  Validation of ASAS MRI lesion definitions in axial spondyloarthritis: Data from the Echography in Spondyloarthritis Cohort (ECHOSPA)
Walter Maksymowych, Canada

08.25 010 Inflammation on MRI of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: The 5 years data of the DESIR cohort
Alexandre Sepriano, The Netherlands

08.35 011 Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active AS: 12-week results from a Phase 2b study
Désirée van der Heijde, The Netherlands

08.45 012 High need for anti-TNF therapy after withdrawal strategy in early peripheral spondyloarthritis
Philippe Carron, Belgium

08.55 013 Dutch recommendations for physical therapy in axial spondyloarthritis (axSpA)
Salima van Weely, The Netherlands

SESSION 8:  Bone and SpA: What’s new

09.05 INV22 Role of ectopic BMP signaling in pathologic ossification and angiogenesis
Maurizio Pacifici, Philadelphia, USA

09.35 INV23 Bone control: Gastrointestinal metabolites on a mission...
Georg Schett, Erlangen, Germany

10.05 INV24 Mechanical stress, how does it impact SpA?
Dirk Elewaut, Gent, Belgium

10.35 Poster Session 3 and Coffee Break

SESSION 9:  Heterotopic new bone formation in SpA: The plot thickens...

11.05 INV25 IL-17, TNF and bone formation, what is the evidence?
Pierre Miossec, Lyon, France

11.35 INV26 Is low radiation CT of the spine suitable to assess structural progression in SpA
Désirée van der Heijde, Leiden, The Netherlands

12.05 INV27 Do we need to bother measuring bone proliferation in axial SpA? Insights from clinical trials
Xenofon Baraliakos, Bochum, Germany

12.35 Closure of the Congress

12.50 Farewell Reception
Poster Session 1 is scheduled during the coffee break of 10.15 - 11.15 hrs on Friday, October 5. The presenters of the posters P1 through P58 are requested to be present at their posters.

P1 Which imaging outcomes for axSpA are most sensitive to change? A 5-year analysis of the DESIR cohort

P2 Which scoring method depicts spinal radiographic damage in (early) axial spondyloarthritis best? Five-year results from the DESIR cohort

P3 Spinal radiographic progression in early axial SpA: 5-year data from the DESIR cohort

P4 Correlation between ultrasound nail changes on psoriatic disease and nail psoriasis severity index comparing with rheumatoid arthritis and healthy controls

P5 Progression of structural damage on MRI of the spine and sacroiliac joints in patients with axial spondyloarthritis is limited: The 5–year results in the DESIR cohort

P6 Magnetic resonance imaging of the cervical spine in patients with rheumatoid arthritis and ankylosing spondylitis presenting with chronic neck pain – A systematic comparison of clinical assessments
Baraliakos X., Soltani M., Kiltz U., Braun J. (Germany)

P7 Analysis of the different value of magnetic resonance imaging changes in the sacroiliac joints for a diagnosis of axial spondyloarthritis as judged by rheumatologists and radiologists
Baraliakos X., Ghadir A., Fruth M., Kiltz U., Braun J. (Germany)

P8 Inflammatory lesions and structural changes of sacroiliac joints on MRI in early axial spondyloarthritis: 2-year follow-up study
Rumiantceva D.G., Dubinina T.V., Demina A.B., Erdes S. (Russia)

P9 Impact of dose tapering of tumour necrosis factor inhibitor on achieving inactive disease as recommended by ‘T2T’ strategy in axial spondyloarthritis: A prospective, nationwide cohort study
Park J.W., Shin K., Song Y.W., Lee E.Y. (Republic of Korea)

P10 Diagnostic value of MRI in non-radiographic axial spondyloarthritis

P11 The damage to the hip joints in ankylosing spondylitis according to x-ray examination
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes Sh.F. (Russia)

P12 MRI assessment of hip joints involvement in ankylosing spondylitis patients
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes S.F. (Russia)

P13 Factors associated with changes in volumetric bone mineral density in patients with ankylosing spondylitis. A five-year prospective study using HRpQCT

P14 The physiological changes of the enthesis in response to age, body mass index and physical activity - An ultrasound study in healthy people
Ureyen S., Solmaz D., Stephenson W., Eder L., Roth J., Aydin S.Z. (Canada)
Poster Session 1

P15 Optimizing the MRI imaging in patients with inflammatory back pain and suspected Axial Spondyloarthritis
Chan A., Mills T., Yoong P. (UK)

P16 Simple radiographic findings of Achilles tendon in symptomatic and asymptomatic posterior heel in Ankylosing Spondylitis
Sung I.H., Kim T.H., Lee J.K. (Korea)

P17 Diagnostic ascertainment of axial spondyloarthritis in patients presenting with undiagnosed back pain: What is the impact of MRI in rheumatological practice?

P18 MRI lesion definitions in axial spondyloarthritis: A consensus reappraisal from the Assessments in SpondyloArthritis International Society (ASAS)

P19 Ability of magnetic resonance imaging to predict remission and relapse in peripheral spondyloarthritis
Renson T., Carron P., Krabbe S., Jans L., De Craemer A., de Hooge M., Jacques P., Østergaard M., Elewaut D., Van den Bosch F. (Belgium & Denmark)

P20 Clinical evaluation correlates poorly with ultrasound and magnetic resonance imaging of joints and entheses in early peripheral spondyloarthritis
Renson T., Carron P., Krabbe S., Jans L., De Craemer A., de Hooge M., Jacques P., Østergaard M., Elewaut D., Van den Bosch F. (Belgium & Denmark)

P21 Consensus definitions for MRI lesions in the sacroiliac joints of patients with axial spondyloarthritis: First analysis from the assessments in spondyloarthritis international society classification cohort

P22 The contribution of structural MRI lesions to detection of sacroilitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort

P23 First validation of consensus definitions for MRI lesions in the sacroiliac joint by the assessments in spondyloarthritis international society (ASAS) MRI group

P24 Which MRI lesions in the sacroiliac joint are associated with the diagnosis of axial spondyloarthritis after 2 years follow up in the Echography in Spondyloarthritis Cohort (ECHOSPA)?

P25 MRI assessment of bone marrow edema in the sacroiliac joints of patients with spondyloarthritis: Is the SPAIR T2w technique comparable to STIR?
Dalto V.F., Luppino-Assad R., Crema M.D., Louzada-Junior P., Nogueira-Barbosa M.H. (Brazil & USA)
Poster Session 1

P26 Validation of a web-based calibration module for the SPARCC MRI SIJ inflammation score based on principles of artificial intelligence

P27 Can sufficient reliability of scoring SIJ structural lesions on MRI be achieved using a web-based calibration module developed on principles of artificial intelligence?

P28 Computer-aided classification of inflammatory sacroiliitis in magnetic resonance imaging

P29 Sacroiliitis in patients with psoriatic arthritis and ankylosing spondylitis - Are there differences?

P30 Radiomics association of MRI texture features with spondyloarthritis and sacriiitis

P31 Spondyloarthritis in a population without access to biologics in 2017 - Padre Hurtado Hospital experience
Ibañez S., Valenzuela O., Villar M., Silva F., Poblete M., Mogollones K., Mardones C. (Chile)

P32 Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriage? Results from the worldwide ASAS cohort

P33 Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known? Data from the ASAS, DESIR, and SPACE cohorts

P34 Diagnostic delay in spondyloarthritis: How can we do better?
Resende G.G., Lage R.C., Malheiro O.B., Guimarães D.L., Bomtempo C.A.S., Carvalho M.A.P. (Brazil)

P35 Cardiac conduction disturbances in patients with ankylosing spondylitis - A Swedish longitudinal cohort study

P36 Factors related to health related quality of life in ankylosing spondylitis, overall and stratified by sex

P37 Osteonectin in cardiovascular risk in axial spondyloarthritis: A serological and genetic study

P38 In vivo phosphorylation of p38 in monocytes is enhanced, at the time of diagnosis, in patients with axial spondyloarthritis (axSpA)
Kuuliala A., Kuuliala K., Koivuniemi R., Hämäläinen M., Moilanen E., Kautiainen H., Repo H., Leirisalo-Repo M. (Finland)
P39 Association of IgA antibodies against CD74 with production of IL17A but not of TNFa in patients with active axial spondyloarthritis
Baraliakos X., Kniesch K., Baerlecken N., Braun J., Witte T. (Germany)

P40 Comparison of retention rates between tumor necrosis factor-α inhibitors in ankylosing spondylitis patients: Data from the Korean College of Rheumatology Biologics registry
Kim H.A., Oh S., Park Y.B., Shin K. (South Korea)

P41 High serum allograft inflammatory factor 1 is associated with poor response to TNFα inhibitors in ankylosing spondylitis
Lee E.E., Lee J.S., Park J.W., Song J., Choi J.Y., Song Y.W., Lee E.Y. (Korea)

P42 Overexpression of macrophage migration inhibitory factor in patients with ankylosing spondylitis and its relation to sex, inflammation and treatment
Kumar A., Do L., Hellman U., Forsblad-d’Elia H. (Sweden)

P43 PROgnostic Markers In axial Spondyloarthritis (PROMISE) – Alpha 1 antitrypsin may identify axSpA patients at risk of uveitis
Reilly E., McGrogan A., Sengupta R. (UK)

P44 Comparing disease status, symptomology, and clinical characteristics of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients in the United States
Deodhar A., Hunter T., Sandoval D., Lobosco S., Moon R., Miligan G. (USA & UK)

P45 Can Smoking Cause Paradoxical Findings in Patients with Psoriatic Arthritis?
Kılıç E., Kılıç G., Nas K., Dağlı A.Z., Tekeoğlu I., Kamanlı A. (Turkey)

P46 Fatigue, health related quality of life and physiologic status in patients with psoriatic arthritis in remission or low disease activity according to different outcome measures
Kılıç G., Kılıç E., Nas K., Kamanlı A., Tekeoğlu I. (Turkey)

P47 Fecal calprotectin, a useful biomarker of microscopic bowel inflammation in patients with spondyloarthritis

P48 Undifferentiated spondyloarthitis in Brazilian patients - Predictors of persistent disease compared to remission after eight years of follow-up
da Cruz Lage R., Bomtempo C.A.S., Kakehasi A.M., Carvalho M.A.P., Resende G.G. (Brazil)

P49 Serum miR-214 as a Novel Noninvasive Biomarker for Ankylosing Spondylitis
Jin S.H., Kook H., Jin H.M., Cho Y.N., Lee S.S., Park Y.W., Kim T.J. (South Korea)

P50 Do n-3 polyunsaturated fatty acids affect ECM remodeling in Psoriatic Arthritis?
Sardar S., Kristensen S., Siebuhrr A.S., Christensen J.H., Karsdal M.A., Schmidt E.B., Schlemmer A., Bay-Jensen A.C. (Denmark)

P51 Impact of TNF inhibition on work outcomes, in Axial Spondyloarthritis
Shim J., Jones G.T., Pathan E.J., Macfarlane G.J. (UK & Canada)

P52 Patients awareness of the disease treatment, disease activity and spinal mobility monitoring before and after educational schools for rheumatologists and the patients with ankylosing spondylitis

P53 Serum Glucocorticoid-Inducible Kinase-1(SGK-1) levels in patients with Ankylosing Spondylitis
Keskin G., Inal A., Keskin D., Olmez U. (Turkey)

P54 Use of MRI and biological therapy in incident patients diagnosed as ankylosing spondylitis and spondyloarthritis: Danish nationwide cohort study 2000-2013
Nygaard A., Ljungdalh P., lachm M., Schiottz-Christensen B. (Denmark)

P55 Disease activity and characteristics of SpA-patients fulfilling ESSG criteria only compared to SpA-patients fulfilling ASAS criteria
Hansen I.M., Bakland G. (Norway)
Poster Session 1

P56 Serum fibroblast growth factor-23 levels were higher in patients with axial spondyloarthritis and may be associated with disease activity
Gercik O., Coban E., Ozbek Iptec B., Avcioglu G., Solmaz D., Bayindir O., Kabadayi G., Kozaci D., Akar S. (Turkey)

P57 Expression of biomarkers in Psoriatic Arthritis
Juneblad K., Rantapää Dahlqvist S., Alenius G.M. (Sweden)

P58 Association between high body mass index and clinical features of axial spondyloarthritis
Yeo J.N., Seo M.R., Ryu H.J., Choi H.J., Baek H.J. (Republic of Korea)

Poster Session 2

Poster Session 2 is scheduled during the coffee break of 16.30 - 17.15 hrs on Friday, October 5. The presenters of the posters P59 through P112 are requested to be present at their posters.

P59 Disease modifying anti rheumatic drugs in the treatment of SAPHO syndrome: Systematic literature analysis
Monet M., Prati C., Guillot X., Sondag M., Verhoeven F., Aubin F., Wendling D. (France)

P60 Treatment outcome with combined methotrexate, sulfasalazine and on-demand NSAIDs in axial spondyloarthritis in a resource-limited real world clinical practice
Ganapati A., Pulukool S., Gowri M., Antonisamy B., Danda D. (India)

P61 Certolizumab pegol in a Spanish cohort of patients with psoriatic arthritis - Preliminary results
Reina D., Mateo L., Prior Á., Laiz A., Moreno M., Juanola X. (Spain)

P62 Evaluation of the work productivity in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients before and after the start of adalimumab therapy in daily practice in Belgium (SpActive Study)
De Clerck L., Maertens M., Remans Ph., Stuer A., Delmotte N., Van den Enden M., Stubbe M. (Belgium)

P63 Canadian observational study assessing the effectiveness of adalimumab vs. non-biologic DMARDs in ankylosing spondylitis (COMPLETE-AS): 12-month data
Bessette L., Khraishi M., Chow A., Pavlova V., Silverberg S., Stewart J., Remple V. (Canada)

P64 Canadian observational study assessing the effectiveness of adalimumab vs. non-biologic DMARDs in psoriatic arthritis (COMPLETE-PsA): 12-month data
Khraishi M., Bessette L., Chow A., Harraoui B., Pavlova V., Stewart J., Remple V. (Canada)

P65 Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
Yahya F., Gaffney K., Sengupta R. (UK & Malaysia)
P66 Efficacy of new treatments on dactylitis of psoriatic arthritis: Update of systematic literature review  
Sondag M., Verhoeven F., Guillot X., Prati C., Wendling D. (France)

P67 The relationship between daily physical activity and tumor necrosis factor inhibitor survival time in patients with ankylosing spondylitis  
Kim T.H., Koo B.S., Shin J.H., Sung I.H. (Korea)

P68 Comparison of continuous use of NSAIDs and on-demand mode in patients with early axial spondyloarthritis  
Erdes S., Rumiantceva D.G., Dubinina T.V., Demina A.B. (Russia)

P69 How to optimize exercise behaviour in axial spondyloarthritis - Results of an intervention mapping study  

P70 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: Results from the 48–week run-in part of C-OPTIMISE  
Landewé R., van der Heijde D., Dougados M., Baraliakos X., Van den Bosch F., Hoepken B., Thomas K., Gensler L S. (The Netherlands, France, Germany, Belgium & USA)

P71 Intravenous golimumab in adult patients with active psoriatic arthritis: Efficacy and safety through 1 Year  

P72 Weight-loss improves disease activity in patients with psoriatic arthritis and obesity  

P73 A flare of sacroilitis under Vedolizumab Therapy for Crohn Disease  
Sunar İ., Yılmaz G., Yalçın A.P., Ataman Ş. (Turkey)

P74 Predicting persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients  
Hunter T., Deodhar A., Bolce R., Schroeder K., Sandoval D. (USA)

P75 Levels of adherence to biologic therapy of spondyloarthritis patients  
Madeira N., Cardoso A., Trinca R., Silva C., Santos H., Miguel C., Barcelos F., Medeiros D., Campanilho Marques R., Cunha Miranda (Portugal)

P76 Secukinumab demonstrates a consistent safety profile over long-term exposure (up to 4 years) in patients with active ankylosing spondylitis - Updated pooled analysis of three phase 3 trials  
Deodhar A., Baraliakos X., Marzo-Ortega H., Sieper J., Martin R., Porter B., Shete A. (USA, Germany, UK & Switzerland)

P77 Secukinumab sustains improvements in signs and symptoms in patients with psoriatic arthritis through 2 years (FUTURE 4)  

P78 Secukinumab efficacy in psoriatic arthritis patients with or without enthesitis at baseline - Pooled analysis from two Phase-III trials over 2 years  
Wallman J. K., Schett G., Mclinnes I. B., Quebe-Fehling E., Rasouliyan L., Pricop L., Fasth A. E., Gaillez C. (Sweden, Germany, UK, Switzerland, Spain & USA)

P79 Reducing avoidable Biologic drug wastage through collaboration between patients and care providers: the Leeds Spondyloarthritis Service experience  
Barr A., Pickles D., Fadl N., Dou J., Vandevelde C., Dubash S., Freeston J.E., Marzo-Ortega H. (UK)

P80 Six-month treatment results for ustekinumab (UST) and TNF inhibitors (TNFi) in psoriatic arthritis (PsA) in Europe (PsABio-Study)  

P81 Immune response profiling reveals signaling networks mediating TNF-blocker function and predictors of therapeautic responses in spondyloarthritis patients  
Menegatti S., Rouilly V., Latis E., Yahia H., Leloup C., Miceli-Richard C., Dougados M., Bianchi E., Rogge L. (France)
### Poster Session 2

#### P82 Switching to biosimilars: What have we learned?

#### P83 Monotherapy with biologics vs combined therapy in patients with Psoriatic Arthritis (Apsor) peripheral

#### P84 Is the clinical and therapeutic profile related to satisfactory response to apremilast in psoriatic arthritis?
De la Morena I., Espinosa M., Godoy H., Martinez Á., Santos C., Martínez A., Fernández M., Fernández-Llanio N., Palma D., Moreno M.J., Haro A., Conesa A., Calvo J. (Spain)

#### P85 Impact of biologics on immune cells in Axial Spondyloarthritis
Rosine N., Koturans, Yahia H., Menegatti S., Leloup C., Bianchi E., Miceli-Richard C., Rogge L. (France)

#### P86 A cross-sectional evaluation of a Brazilian spondyloarthritis single-center tertiary cohort: Clinical and treatment data
Shimabuco A., de Moraes J.C.B., Sampaio-Barros P., Goldenstein-Schainberg C., Gonçalves C.R., Saad C.G.S. (Brazil)

#### P87 Personalising care: Using infliximab drug trough and anti-drug antibody levels is a safe and cost effective treatment strategy in Spondyloarthritis

#### P88 The effect of biologic disease-modifying antirheumatic drugs (bDMARDs) in targeting disease remission in Axial Spondyloarthritis (axSpa): A systematic literature review (SLR)

#### P89 The GO-DACT protocol: A randomized controlled trial to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesitis, in MTX naive psoriatic arthritis patients
Vieira-Sousa E., Canhão H., Fonseca J.E. on behalf of the GO-DACT research team (Portugal)

#### P90 Tumor necrosis factor inhibitors persistence in psoriatic arthritis patients

#### P91 Remission rates of biologic-treated spondyloarthritis and psoriatic arthritis patients

#### P92 Dispensation of immunobiologicals in model of assisted therapy in the SUS reduces costs with immunobiological in ankylosing spondylitis

#### P93 Demyelination associated with anti-TNFa treatment in spondyloarthritis patients - A single-center experience
Kougkas N., Vourakis G., Avgoustidis N., Mitsias P.D., Sidiropoulos P, Mastorodemos V.C., Bertsias G. (Greece & USA)

#### P94 Psoriasis- and inflammatory bowel disease models co-operate with biomechanical stress in triggering mild joint inflammation
Gulino G.R., Van Mechelen M., Lories R. (Belgium)

#### P95 The JAK1 selective inhibitor filgotinib regulates both enehtesis and colon inflammation in a mouse model of psoriatic arthritis
Poster Session 2

P96 mTOR blockade by rapamycin decreases arthritis and spondylitis development and severity in HLA-B27 transgenic rats
Chen S., van Tok M., Pots D., Taurog J., van de Sande M., Baeten D., van Duivenvoorde L. (The Netherlands & USA)

P97 Certolizumab pegol like mice equivalent reduces inflammation and bone damage in transmembrane TNF transgenic mice

P98 Exploring the ankylosing spondylitis-associated regulatory SNPs at the RUNX3 locus
Vecellio M., Cohen C.J., Fischer R., Wordsworth B.P. (UK)

P99 Chronic back pain (CBP) in first degree relatives (FDR’s) of patients with ankylosing spondylitis - Predictive value of HLA-B27 and persistence of the inflammatory back pain over time

P100 Intracellular activity of protein phosphatase magnesium-dependent 1A regulates bone metabolism in ankylosing spondylitis
Kim Y.G., Yoo B., Kim T.H., Chang E.J. (Korea)

P101 IL-23 induction of MDL-1+ myeloid cells is critical in the pathogenesis of psoriatic arthritis
Nguyen C.T., Hui D., Kang M., Gu R., Adamopoulos I.E. (USA)

P102 Proteomic and transcriptomic profiling of cells in ankylosing spondylitis patients identifies a novel, synovial-resident CD8+ T cell
Qaiyum Z., Gracey E., Yao Y., Inman R.D. (Canada)

P103 Tyk2 promotes IL-23-induced type 3 immunity and disease progression in spondyloarthritis
Gracey E., Muller M., Miao W., Westlin W., Inman R.D. (Canada, Austria & USA)

P104 MicroRNAs deregulation in monocytes and CD4+ T-lymphocytes from patients with axial spondyloarthritis

P105 Development of a 19-parameter flow cytometry panel to analyze killer immunoglobulin-like receptor (KIR)-expressing lymphocytes in ankylosing spondylitis
Sharma N., Lee J., Ermann J. (USA)

P106 IL-22-expressing but not IL-17A-expressing group 3 innate lymphoid cells are expanded in the inflamed spondyloarthritids joint

P107 Histological evidence that mast cells act as promoters rather than regulators of IL-17A-mediated tissue inflammation in spondyloarthritis

P108 RORyt inhibition selectively targets pathogenic subsets of human iNKT and γδ-T cells enriched in Spondyloarthritis while preserving IL-22 responses
Venken K., Mortier C., Labadia M.E., Jacques P., Decruy T., Coudenys J., Hoyt K., Van Gassen S., Wahle J., Saets Y., Van Den Bosch F., Nabozy G., Elewaut D. (Belgium & USA)

P109 Screening for antibody reactivity in early axial spondyloarthritis identifies novel antigenic targets
Quaden D., Vandormael P., Corten K., Vandenabeele F., Vanhoof J., Geusens P., Somers V. (Belgium & The Netherlands)

P110 A probable role of HSP60 in the pathogenesis of spondyloarthritis

P111 An enthesial innate immune cell biological basis for differential efficacy of PDE4 and IL-23 pathway blockade between Psoriatic Disease and Rheumatoid Arthritis

P112 Regulation of cytokine production by iNKT cells requires IRE1α
Poster Session 3 is scheduled during the coffee break of 10.35 - 11.05 hrs on Saturday, October 6. The presenters of the posters P113 through P166 are requested to be present at their posters.

P113  **Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis**  
Lee K.A., Kim H.R., Lee S.H. (South Korea)

P114  **Performance of referral strategies for spondyloarthritis: A population-based nationwide study**  

P115  **Integrated longitudinal analysis increases precision and reduces bias: A comparative 5-year analysis in the DESIR Cohort**  

P116  **High prevalence of axial spondyloarthritis in patients with anterior uveitis and chronic back pain – Preliminary results of the Sp-EYE study**  

P117  **Computer tomography defined sacroiliitis in Inflammatory Bowel Disease – A service evaluation of reporting standards**  
Lim C.S.E., Low B.L.S., Dhillon B., Azegami S., Toms A., Gaffney K. (UK)

P118  **Comparison of work disability, depression, and quality of life in ankylosing spondylitis vs psoriatic arthritis: Interim results from the COMPLETE studies**  
Khraishi M., Bessette L., Harauwi B., Florica B., Setty Y., Teo M., Remple V. (Canada)

P119  **Impact of extra-articular manifestations on patient-reported outcomes in ankylosing spondylitis and psoriatic arthritis: Interim results from the COMPLETE studies**  
Bessette L., Khraishi M., Florica B., Setty Y., Teo M., Remple V. (Canada)

P120  **Asas consensus on Spanish nomenclature for spondyloarthritis**  

P121  **Comparison of clinical and imaging arms of the Assessment of Spondyloarthritis International Society (ASAS) classification criteria and parameters of objective inflammation in patients with non-radiographic axial spondyloarthritis (nr-axSpA)**  

P122  **Spinal mobility measures allow discrimination of subgroups of different activity and severity in early axial spondyloarthritis**  

P123  **Measuring spinal mobility over time in early axial spondyloarthritis: Can we do it reliably?**  

P124  **Influence of inflammation and structural damage on global functioning in patients with axial spondyloarthritis - Using the ASAS Health Index in routine care**  
Kiltz U., Wiatr T., Baraliakos X., Fedorov K., Braun J. (Germany)

P125  **Osteoporosis commonly occurs in axial spondyloarthropathy**  
Fitzgerald G.E., Anachebe T., McCarron K., O’ Shea F. (Ireland)

P126  **Syndesmophytes prevent accurate DXA assessment of the spine in axial spondyloarthropathy**  
Fitzgerald G.E., Anachebe T., McCarron K., O’ Shea F. (Ireland)

P127  **Add-on effect of aerobic exercise to stretching in patients with ankylosing spondylitis**  
Kim H.W., Park J., Kim D., Park J.H., Park M.C. (Korea)
P128 Assessment of early myocardial dysfunction using speckle tracking echocardiography in patients with radiographic and nonradiographic axial spondyloarthritis
Emren V., Gercik O., Ozdemir E., Solmaz D., Gucenmez S., Eren N., Tokac M., Kabadayi G., Akar S. (Turkey)

P129 ASAS, BASDAI and ASDAS remission in secukinumab treated patients with active ankylosing spondylitis: 3-year results from a pooled analysis of two phase 3 studies
Baraliakos X., Van den Bosch F., Machado P., Gensler L., Bintu S., Porter B., Gaillez C., Deodhar A. (Germany, Belgium, UK, USA & Switzerland)

P130 The European Map of Axial Spondyloarthritis (EMAS) - Living with the condition

P132 Assessing functional disability and general health situation in patients with Ankylosing Spondylitis by ASAS health index
Can M. (Turkey)

P133 Empowering Ankylosing Spondylitis (AS) patients through an online personal health system
Eren O., Gençtürk M., Yüksel M. (Turkey)

P134 Prevalence and characterization of psoriatic arthritis mutilans patients from a single tertiary center

P135 The status of health in patients with axial spondyloarthritis (axSpA) as determined by the Assessment of SpondyloArthritis International Society Health Index (ASAS-HI)

P136 Is the delay from recognition of severe active axial spondyloarthritis to biologic disease modifying therapy initiation improving?
Williams T., Wadeley A., Cavill C., Freeth M., Sengupta R. (UK)

P137 Axial Spondyloarthritis-related quality of life improves significantly following initiation of biological disease-modifying therapyWilliams T., Wadeley A., Cavill C., Freeth M., Sengupta R. (UK)

P138 Work productivity among workers with axial spondyloarthritis
Lopes C., Rodrigues-Manica S., Marona J., Mateus M., Pimentel-Santos F., Branco J. (Portugal)

P139 Improvement of cytological grade and tear production in Ankylosing Spondylitis patients under anti-TNF therapy: A long-term follow-up
Emergence of severe spondyloarthropathy related entheseal pathology in Vedolizumab treated Inflammatory Bowel Disease

Patient-acceptable symptom state in psoriatic arthritis: Prevalence and associated factors in real clinical practice
Queiro R., Cañete J.D., Montilla C., Abad M.A., Gómez S., Cábez A. (Spain)

Vitamin D deficiency is associated with greater presence of vertebral fractures, in patients with axial spondyloarthritis
Romera-Lopez C., Fernández-Carballido C., Martínez-Vidal M.P., Pedraz Penalva T., García Moreno M.A. (Spain)

Osteoporosis and vertebral fractures are associated with disease activity and axial radiographic damage in axial spondyloarthritis - 206 Spanish patient’s series
Romera-López C., Fernández-Carballido C., Martinez-Vidal M.P., Pedraz Penalva T., García Moreno M.A. (Spain)

Validity of PROMIS measures in ankylosing spondylitis patients
Hwang M.C., Ogdie A.R., Reveille J.D. (USA)

Patients with axial spondyloarthritis rarely have 1 or 2 inflammatory back pain parameters
de Hooge M., Varkas G., Elewaut D., van den Bosch F. (Belgium)

Relationship between thoracic kyphosis and shoulder muscle strength and shoulder joint motion in male patients with ankylosing spondylitis
Mete O., Sarac D.C., Baglan Yentur S., Tore G., Sari F., Ataş N., Göker B., Oskay D. (Turkey)

Diagnostic performance of power Doppler ultrasound of the entheses in patients with uncertain diagnosis of spondyloarthritis: The EchoSpA prospective multicenter French cohort

A study of the HLA-B*27-associated microbiota in healthy individuals reveals intestinal dysbiosis and an altered microbiota-specific immune response may be predisposing events in the pathophysiology of spondyloarthritis

A study of microbial translocation in an animal model of spondyloarthritis
Asquith M., Slleisman M., Davin S., Stauffer P., Karstens L., Rosenbaum J.T. (USA)

The response to TNF-blockers treatment of SpA patients is influenced by the interplay between HLA-B27 and gut microbiota composition at baseline
Vallier M., Dougados M., Ferreira S., Menegatti S., Bianchi E., Rogge L., Chamaillard M., Miceli-Richard C. (France)

Fungi overlooked: The mycobiome as a cause of spondyloarthritis (SpA)
Rosenbaum J.T., Laurence M., Asquith M.J. (USA & Canada)

Specific alterations in the enteric virome in the subclinical gut inflammation of AS patients drive innate immune alterations
Ciccia F., Guggino G., Macaluso F., Rizzo A. (Italy)

Is calprotectin a useful diagnostic tool in diagnosing spondyloarthropathies?
Van Hoovels L., Schiemsky T., Cauchie M., Van Den Bremt S., Vander Cruyssen B., Bossuyt X., Stubbe M. (Belgium)

Features of chronic pain syndrome in patients with ankylosing spondylitis
Filatova E.S., Erdes S. (Russia)

Efficiency of long term educational programs for physicians in early diagnosis and treatment of axial spondiloarthritis in Kazan
Lapshina S., Myasoutova L. (Russia)

Preliminary results of development and 12 months follow up test of the mobile application for patients with axial spondyloarthritis
Rumiantceva D.G., Dubinina T.V., Sitalo A.V., Erdes S. (Russia)
P158  Pain beliefs and disability in chronic “inflammatory” and “non-inflammatory” low back pain
Yilmaz Z. (Turkey)

P159  Rapid onset of efficacy in patients with active psoriatic arthritis treated with Ixekizumab: A pooled analysis of data from two phase III clinical trials
Deodhar A., Papp K., Shuler C.L., Park S.Y., Kvien T. (USA, Canada & Norway)

P160  Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life (QoL) in patients with active psoriatic arthritis (PsA)
Kavanaugh A., Birt J., Lin C-Y., Benichou O., Hufford M.M., Gottlieb A.B., Van Beneden K. (USA & Belgium)

P161  Health utility estimates in economic evaluations in axial spondyloarthritis - Different methods, different results

P162  Fibrodysplasia Ossificans Progressiva as a clinical model of new bone formation
Nikishina I., Latypova A., Arsenyeva S., Kaleda M., Alekseev D. (Russia)

P163  Russian Spondyloarthritis assessment groups’ definition and criteria of remission in Axial Spondyloarthritis

P164  Assessment of lumbar spinal mobility using inertial measurement units in axial spondyloarthritis
Franco L., Ward W., Sengupta R., Cazzola D. (UK)

P165  The prevalence of rheumatological diseases and psoriasis in the first-degree relatives of PsA patients
Nas K., Remzi Çevik R., Dağlı A.Z., Tekeoglu İ., Kamanlı A., Sağ S. (Turkey)

P166  Association of work instability with fatigue and emotional status in patients with ankylosing spondylitis - Comparison with healthy controls
Ulus Y., Akyo, Y., Bilgici A., Kuru O. (Turkey)

Registration

<table>
<thead>
<tr>
<th>Activity</th>
<th>Until 10/07/18</th>
<th>As of 11/07/18</th>
<th>As of 15/09/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant MD</td>
<td>€ 600,00</td>
<td>€ 650,00</td>
<td>€ 700,00</td>
</tr>
<tr>
<td>Researcher Non-MD with Abstract*</td>
<td>€ 350,00</td>
<td>€ 400,00</td>
<td>€ 400,00</td>
</tr>
<tr>
<td>Student with Abstract*</td>
<td>€ 350,00</td>
<td>€ 400,00</td>
<td>€ 400,00</td>
</tr>
<tr>
<td>Industry Participant</td>
<td>€ 800,00</td>
<td>€ 850,00</td>
<td>€ 900,00</td>
</tr>
<tr>
<td>Gala Dinner on Friday, October 5</td>
<td>€ 75,00</td>
<td>€ 75,00</td>
<td>€ 75,00**</td>
</tr>
</tbody>
</table>

*Presenting author only
**If seats are available

The registration includes
The registration fee includes access to all lectures, to the Opening Reception and Walking Dinner, the lunches, coffee breaks and the Farewell Reception as indicated in the programme. Participants also have free access to the exhibition. Participation into the Opening Reception & Walking Dinner and the Farewell Reception is free but pre-registration is mandatory. Separate registration and payment is required to participate in the Gala Dinner.

Payment
Payment is to be made by credit card. All major credit cards are accepted.

Cancellations
Cancellations received no later than August 31, 2018, entitle registered persons to a 50% refund. In order to cancel your registration and/or hotel booking please contact Laurence Schepens: laurence@medicongress.com.
A number of hotel rooms have been booked at special group rates, including breakfast and VAT. The below rates are only valid for reservations made through Medicongress. Housing requests are filled in order of receipt. If the hotel of your choice is filled, you will be assigned to another hotel. Hotel availability cannot be guaranteed after August 15.

Any requests for hotel accommodation must be accompanied by a credit card number, in order to secure the room. This credit card will not be charged by the organisers but only serves as a reservation guarantee. Participants will have to pay their hotel room and personal expenses at the reception of the hotel. In case of late cancellation or no show, the room will be charged on the credit card.

A hotel confirmation will be sent by email after receipt of the registration form and housing request and payment of the registration fee.

Each hotel has its proper cancellation policy. For details, see the hotel accommodation section of www.spa-congress.org.

List of hotels and group rates for the SpA Congress:

**Ibis Gent Opera**
- Single room: € 104,00
- Double room: € 122,00
  Breakfast is included. City tax: € 3,00/person/night.

**Ibis Budget Gent Centrum Dampoort**
- Single room: € 74,00
  Breakfast and city taxes are included.

**Holiday Inn Express Gent***
- Single room: € 147,00
- Double room: € 147,00
  Breakfast is included. City tax: € 3,00/person/night.

**Hotel Best Western – Cour St. Georges***
- Single room: € 129,00
- Double room: € 149,00
  Breakfast is included. City tax: € 3,00/person/night.

**Hotel Gravensteen***
- Standard Single room: € 125,00
- Standard Double room: € 135,00
- Executive Single room: € 135,00
- Executive Double room: € 145,00
  Breakfast is included. City tax: € 3,00/person/night.

**Ghent River Hotel****
- Standard Single room: € 144,00
- Standard Double room: € 154,00
- Executive Single room: € 154,00
- Executive Double room: € 164,00
  Breakfast is included. City tax: € 3,00/person/night.
Social Programme

Opening Reception and Walking Dinner on Thursday, October 4
This Opening Reception and Walking Dinner will take place at Flanders Opera House and is included in the registration fee. Pre-registration however is required.

Gala Dinner on Friday, October 5

The Gala Dinner will take place at the ‘Handelsbeurs’. Separate registration and payment is required to participate in the Gala Dinner.
The Handelsbeurs is located on the Kouter square, well-known for its 19th century stately buildings and for its flower market on Sundays. The Handelsbeurs is located at a mere stone’s throw from Flanders Opera House.

Farewell Reception on Saturday, October 6
The Farewell Reception will take place at Flanders Opera House and is included in the registration fee. Pre-registration however is required.

General Information

Venue
Flanders Opera House – Vlaamse Opera
Schouwburgstraat 3
9000 Gent
https://vlaamseopera.be/en

Flanders Opera House – Vlaamse Opera is located in the city centre, within walking distance from the hotels.

Date
Thursday, October 4 - Saturday, October 6, 2018

Language
The official congress language is English.

Exhibition
A medical exhibition is held on the occasion of the Congress and is located on the 2nd floor. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Catering
Coffee breaks and lunches will be served in the exhibition area located on the 2nd floor.

WiFi
Free WiFi is offered to all participants and exhibitors. The WiFi access code will be available onsite.

Liability
Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Organisation and Administration
MEDICONGRESS
Noorwegenstraat 49
B-9940 Evergem, Belgium
Phone: +32 (0)9 218 85 85
Fax: +32 (0)9 344 40 10
E-mail: congresses@medicongress.com

Programme developed in collaboration with Wonder Reizen, Lic. A 5603